Bivatuzumab Biosimilar – Anti-CD44 , CD44V mAb – Research Grade

Introduction

Bivatuzumab Biosimilar, also known as Anti-CD44, CD44V mAb, is a monoclonal antibody that targets the CD44 protein. CD44 is a cell surface glycoprotein that is involved in cell adhesion, migration, and signaling. It is overexpressed in many cancer types and has been identified as a therapeutic target for cancer treatment. Bivatuzumab Biosimilar is a research grade antibody that has shown promising results in preclinical studies and is currently being investigated for its potential in cancer therapy.

Structure of Bivatuzumab Biosimilar

Bivatuzumab Biosimilar is a fully humanized IgG1 monoclonal antibody. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of Bivatuzumab Biosimilar is designed to specifically bind to the CD44 protein, while the constant region is responsible for effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Activity of Bivatuzumab Biosimilar

The main activity of Bivatuzumab Biosimilar is the specific binding to the CD44 protein. This binding prevents the interaction of CD44 with its ligands, which are involved in various cellular processes such as cell adhesion, migration, and signaling. By blocking these interactions, Bivatuzumab Biosimilar inhibits the growth and survival of cancer cells that overexpress CD44.

In addition, Bivatuzumab Biosimilar can also induce ADCC and CDC. These effector functions involve the recruitment and activation of immune cells, such as natural killer (NK) cells and macrophages, to kill cancer cells. This mechanism of action makes Bivatuzumab Biosimilar a promising candidate for cancer immunotherapy.

Application of Bivatuzumab Biosimilar

Bivatuzumab Biosimilar is currently being investigated for its potential in cancer therapy. Preclinical studies have shown that Bivatuzumab Biosimilar has anti-tumor activity in various cancer types, including head and neck cancer, breast cancer, and pancreatic cancer. It has also been shown to enhance the efficacy of chemotherapy and radiotherapy in combination treatments.

Moreover, Bivatuzumab Biosimilar has shown promising results in clinical trials. In a phase I/II study, Bivatuzumab Biosimilar was well tolerated and showed anti-tumor activity in patients with head and neck cancer. In another phase I/II study, Bivatuzumab Biosimilar in combination with chemotherapy showed promising results in patients with advanced pancreatic cancer.

Conclusion

Bivatuzumab Biosimilar, also known as Anti-CD44, CD44V mAb, is a research grade monoclonal antibody that specifically targets the CD44 protein. Its main activity is the inhibition of CD44-mediated cellular processes, as well as the induction of ADCC and CDC. Bivatuzumab Biosimilar has shown promising results in preclinical and clinical studies, making it a potential candidate for cancer therapy. Further research and clinical trials are needed to fully evaluate the efficacy and safety of Bivatuzumab Biosimilar in cancer treatment.